Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Other Non-Current Liabilities of $70.0 million for Q1 2026, down 4.05% year-over-year from $73.0 million in Q1 2025, and down 2.5% quarter-over-quarter from $71.8 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $70.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 4.05% year-over-year to $70.0 million; the TTM figure through Mar 2026 stood at $70.0 million (down 4.05% YoY), while the FY2025 annual figure was $71.8 million, down 15.98% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $70.0 million, down from $71.8 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $85.5 million in Q1 2024, with the low at $300000.0 in Q4 2023.
- The 5-year median for Other Non-Current Liabilities is $73.0 million (2025), against an average of $55.8 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities tumbled 98.45% in 2023, then soared 28393.0% in 2024.
- Amneal Pharmaceuticals' Other Non-Current Liabilities stood at $3.3 million in 2022, then plunged by 90.88% to $300000.0 in 2023, then jumped by 28393.0% to $85.5 million in 2024, then fell by 15.98% to $71.8 million in 2025, then slipped by 2.5% to $70.0 million in 2026.
- Business Quant data shows AMRX's Other Non-Current Liabilities at $70.0 million in Q1 2026, $71.8 million in Q4 2025, and $74.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Amneal Pharmaceuticals | 5.70 Bn | 5.57 Bn | 334.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.83 Mn |
| Mar 31, 2026 | 70.02 Mn |
| Dec 31, 2025 | 71.82 Mn |
| Sep 30, 2025 | 74.48 Mn |
| Jun 30, 2025 | 74.48 Mn |
| Mar 31, 2025 | 72.98 Mn |
| Dec 31, 2024 | 85.48 Mn |
| Sep 30, 2024 | 85.48 Mn |
| Jun 30, 2024 | 85.48 Mn |
| Mar 31, 2024 | 85.48 Mn |
| Dec 31, 2023 | 300,000.00 |
| Sep 30, 2023 | 6.01 Mn |
| Jun 30, 2023 | 1.23 Mn |
| Mar 31, 2023 | 41.46 Mn |
| Dec 31, 2022 | 3.29 Mn |
| Sep 30, 2022 | 78.26 Mn |
| Jun 30, 2022 | 79.21 Mn |
| Mar 31, 2022 | 32.87 Mn |
| Dec 31, 2021 | 38.90 Mn |
| Sep 30, 2021 | 60.80 Mn |